SCHEMBL7501498

SCHEMBL7501498

N#Cc1ccc(Cc2ccncc2C=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 7/20 0.47
CYP11B1 P15538 6/20 0.47
HRH3 Q9Y5N1 1/20 0.44
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
SAE1 Q9UBE0 1/20 0.39
UBA2 Q9UBT2 1/20 0.39
LOXL2 Q9Y4K0 2/20 0.39
CYP19A1 P11511 5/20 0.38
CYP2A6 P11509 1/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7527570 0.88 CYP11B2 (0.47) CYP11B2CYP11B1HRH3KDM4EALDH1A1
SCHEMBL9018815 0.78 LOXL2 (0.43) CYP11B2CYP11B1HRH3ALDH1A1SAE1
SCHEMBL7529758 0.77 CYP11B2 (0.51) CYP11B2CYP11B1HRH3KDM4EALDH1A1
SCHEMBL7814470 0.76 LOXL2 (0.54) CYP11B2CYP11B1HRH3KDM4EALDH1A1
SCHEMBL2511386 0.75 SLC22A12 (0.49) CYP11B2CYP11B1
SCHEMBL171234 0.73 HRH3 (0.53) CYP11B2CYP11B1HRH3KDM4EALDH1A1
SCHEMBL14872350 0.71 CYP2A6 (0.42) CYP1A2CYP2D6CYP2C9CYP2C19LOXL2
SCHEMBL31068616 0.71 CYP2A6 (0.42) CYP1A2CYP2D6CYP2C9CYP2C19LOXL2
SCHEMBL7519629 0.71 CYP11B1 (0.51) CYP11B2CYP11B1HRH3KDM4EALDH1A1
SCHEMBL24212085 0.70 HTT (0.46) ALDH1A1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020156113-A1 Farnesyl transferase inhibitors; anticancer agents LES LABORATOIRES SERVIER (FR) 2002-10-24 US disclosed
WO-2002057257-A1 CYCLO`C!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREFOR LES LABORATOIRES SERVIER (FR) 2002-07-25 WO disclosed
WO-2002057258-A1 CYCLO`D!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREOF LES LABORATOIRES SERVIER (FR) 2002-07-25 WO disclosed
EP-1225170-A2 Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier S.A. (FR) 2002-07-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156113-A1 Farnesyl transferase inhibitors; anticancer agents COASY, FNTA, FNTB CYP11B2 399/4885CYP11B1 147/4885HRH3 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.